caba-201
Recombinant proteinexperimental
Clinical trial activity
4 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
4
Phase 2
4
Phase 3
0
Phase 4
0
Earliest trial started Oct 13, 2023 (NCT06121297)
Timeline
2020s
- Jan 1, 2023
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- B-lymphocyte antigen CD19BINDING AGENT
CD19 binding agent
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07006805 | Phase 1/Phase 2 (Phase 2) | Jun 30, 2026 | Cabaletta Bio |
| NCT06359041 | Phase 1/Phase 2 (Phase 2) | Oct 31, 2024 | Cabaletta Bio |
| NCT06328777 | Phase 1/Phase 2 (Phase 2) | Jul 2, 2024 | Cabaletta Bio |
| NCT06121297 | Phase 1/Phase 2 (Phase 2) | Oct 13, 2023 | Cabaletta Bio |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Cabaletta Bio | For profit | 4 | 4 | 1 | 2023 |
1 organizations
Page 1 / 1